McKesson Co. (NYSE:MCK) Shares Bought by West Oak Capital LLC

West Oak Capital LLC grew its stake in McKesson Co. (NYSE:MCK) by 867.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,000 shares of the company’s stock after buying an additional 2,690 shares during the period. West Oak Capital LLC’s holdings in McKesson were worth $1,710,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of MCK. Old North State Trust LLC increased its stake in McKesson by 1.6% during the 3rd quarter. Old North State Trust LLC now owns 1,138 shares of the company’s stock worth $563,000 after buying an additional 18 shares during the period. Black Diamond Financial LLC increased its position in shares of McKesson by 1.3% during the third quarter. Black Diamond Financial LLC now owns 1,525 shares of the company’s stock worth $754,000 after acquiring an additional 19 shares during the last quarter. QV Investors Inc. lifted its stake in shares of McKesson by 0.6% in the third quarter. QV Investors Inc. now owns 3,499 shares of the company’s stock worth $1,730,000 after acquiring an additional 20 shares in the last quarter. ASB Consultores LLC boosted its holdings in McKesson by 2.4% in the third quarter. ASB Consultores LLC now owns 879 shares of the company’s stock valued at $435,000 after purchasing an additional 21 shares during the last quarter. Finally, Old Port Advisors grew its stake in McKesson by 1.3% during the 3rd quarter. Old Port Advisors now owns 1,742 shares of the company’s stock valued at $861,000 after purchasing an additional 22 shares in the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Trading Down 1.4 %

MCK traded down $8.53 during trading on Friday, reaching $581.73. 597,052 shares of the company were exchanged, compared to its average volume of 615,492. McKesson Co. has a 52 week low of $464.42 and a 52 week high of $637.51. The firm has a 50 day moving average of $591.44 and a 200 day moving average of $561.65. The stock has a market cap of $73.84 billion, a P/E ratio of 30.13, a PEG ratio of 1.25 and a beta of 0.52.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, topping the consensus estimate of $6.88 by $0.19. The business had revenue of $93.65 billion during the quarter, compared to analyst estimates of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The company’s quarterly revenue was up 21.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.23 earnings per share. As a group, analysts forecast that McKesson Co. will post 32.73 earnings per share for the current fiscal year.

McKesson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 2nd. Investors of record on Monday, December 2nd were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date of this dividend was Monday, December 2nd. McKesson’s dividend payout ratio (DPR) is 14.71%.

Analyst Ratings Changes

MCK has been the subject of several research analyst reports. Wells Fargo & Company increased their target price on McKesson from $535.00 to $641.00 and gave the company an “equal weight” rating in a research note on Friday, December 13th. StockNews.com upgraded shares of McKesson from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. Leerink Partners dropped their target price on shares of McKesson from $665.00 to $630.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Robert W. Baird raised shares of McKesson from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $531.00 to $688.00 in a research report on Thursday, November 7th. Finally, Bank of America lowered their price objective on McKesson from $680.00 to $650.00 and set a “buy” rating for the company in a report on Monday. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and an average price target of $646.14.

Insider Activity at McKesson

In related news, EVP Leann B. Smith sold 579 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total value of $331,645.41. Following the completion of the transaction, the executive vice president now owns 864 shares in the company, valued at $494,890.56. This represents a 40.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.11% of the stock is owned by insiders.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.